Saturday 07 December 2024
Salisbury Foundation Trust

FOI_7328

Internal Reference Number: FOI_7328

Date Request Received: 26/07/2023 00:00:00

Date Request Replied To: 15/08/2023 00:00:00

This response was sent via: By Email

Request Summary: Nivolumab

Request Category: Companies

 
Question Number 1:
In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

• Ipilimumab (monotherapy)
• Nivolumab (monotherapy)
• Nivolumab AND Ipilimumab (combination)
• Pembrolizumab
• Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
• Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
 
Answer To Question 1:
N/A - we don’t treat these tumour groups at this Trust.
 
Question Number 2:
In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?

• Nivolumab (monotherapy)
• Nivolumab + Ipilimumab
• Nivolumab + Cabozantinib
• Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
 
Answer To Question 2:
N/A - we don’t treat these tumour groups at this Trust.
 
Question Number 3:
In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:

• Nivolumab monotherapy or in combination with Ipilimumab
• Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
• Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
 
Answer To Question 3:
• Nivolumab monotherapy or in combination with Ipilimumab - <5
• Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) - 0
• Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) - 0
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury NHS Foundation Trust
Trust Values